ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Nurexone Biologic Inc

Nurexone Biologic Inc (NRX)

0.72
0.01
( 1.41% )
Updated: 10:00:44

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.72
Bid
0.70
Ask
0.72
Volume
18,164
0.71 Day's Range 0.72
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.71
Open
0.71
Last Trade
1000
@
0.72
Last Trade Time
10:00:44
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
48,249,000
Dividend Yield
-
PE Ratio
-9.55
Earnings Per Share (EPS)
-0.08
Revenue
-
Net Profit
-3.64M

About Nurexone Biologic Inc

Sector
Miscellaneous Metal Ores,nec
Industry
Pharmaceutical Preparations
Headquarters
Toronto, Ontario, Can
Founded
2011
Nurexone Biologic Inc is listed in the Miscellaneous Metal Ores sector of the TSX Venture Exchange with ticker NRX. The last closing price for Nurexone Biologic was $0.71. Over the last year, Nurexone Biologic shares have traded in a share price range of $ 0.00 to $ 0.00.

Nurexone Biologic currently has 48,249,000 shares outstanding. The market capitalization of Nurexone Biologic is $34.26 million. Nurexone Biologic has a price to earnings ratio (PE ratio) of -9.55.

NRX Latest News

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical...

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company...

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company...

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company...

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

TORONTO and HAIFA, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company...

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company...

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce compelling...

NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical...

NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences

TORONTO and HAIFA, Israel, Aug. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that its...

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

Company demonstrates reliable production from multiple biological sourcesThese manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ETUE2gold Inc
$ 0.01
(100.00%)
551.28k
DMDataMetrex AI Limited
$ 0.01
(100.00%)
16.19k
NZNew Zealand Energy Corp
$ 0.95
(46.15%)
18.22k
YFIEdgewater Wireless Systems Inc
$ 0.05
(42.86%)
196.75k
KOVOKovo+ Holdings Inc
$ 0.055
(37.50%)
3k
PLRBPluribus Technologies Corp
$ 0.04
(-55.56%)
6k
BNZBonanza Mining Corporation
$ 0.015
(-50.00%)
8.37k
TVITVI Pacific Inc
$ 0.005
(-50.00%)
3k
MVYMoovly Media Inc
$ 0.005
(-50.00%)
6.5k
AQSAequus Pharmaceuticals Inc
$ 0.005
(-50.00%)
2k
CSTRCryptoStar Corp
$ 0.035
(16.67%)
1.37M
MAEMaritime Resources Corp
$ 0.055
(0.00%)
755k
AECAnfield Energy Inc
$ 0.115
(4.55%)
727.3k
NSENew Stratus Energy Inc
$ 0.56
(-22.22%)
676.52k
BHSBayhorse Silver Inc
$ 0.055
(10.00%)
577.18k

Discussion

View Full Feed
Zardiw Zardiw 4 minutes ago
Lol.......Well, if you had your family with you, your grandkids would make it......lol.......

Z
georgie18 georgie18 4 minutes ago
XRP/USD...$2.71...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 666373

Monday, December 02, 2024 7:47:30 AM

Post#
666411
of 666447
XRPUSD...$2.39...🥳Looking for $3.29 Resistance spot...
XRPUSD
DiscoverGold DiscoverGold 4 minutes ago
$TSLA closed the month strong, with the BX Trender still, signaling continued bullish accumulation
By: Peter DiCarlo | December 1, 2024

• $TSLA closed the month strong, with the BX Trender still, signaling continued bullish accumulation.

Despite last week’
TSLA
navycmdr navycmdr 5 minutes ago
Congress NOT Required for GSE Release - TRUMP WILL NOT Wait for Congress

TRUMP will Have new Treasury & New FHFA RELEASE as "PROMISED"
FNMA
surfkast surfkast 5 minutes ago
Correct that he has done noting. Pumpers trying to convince marks that a Nevada SOS name change mean something.
Too bad the OTCM and FINRA do not recognize it! SMH
Also link back to some great factual DD posted by Hi_Lo
GVSI
Good Vibrations Shoes Inc.
Common Stock
GVSI OTCM
shurtha2000 shurtha2000 5 minutes ago
You caught the bottom here
kaisdaboss88 kaisdaboss88 5 minutes ago
$DPUI pink current catching volume low float 597mil 
DPUI
Sammy boy Sammy boy 5 minutes ago
2.50 coming
FMCC
otterman otterman 5 minutes ago
How many times is the new batch of shareholders going to fall for the 'pivot'?

From 2002 to 2013 Linda 'pivoted' 11 times resulting in 12 failed ventures, most of which never got off the ground.
DBMM
BEIJING BILL BEIJING BILL 5 minutes ago
Oh another another smarty pants here. 
Bravo fornyou
POET
JOoa0ky JOoa0ky 5 minutes ago
Good Morning Three Fifty Wall ♥️
FNMA
boston127 boston127 5 minutes ago
Agree. But with the great year

the NYSE and Naz have had, folks will be selling their losers to offset gains from selling their winners. The January Effect could be a tsunami here, if the company is able to perfrom.
IGPK
Smartypants2 Smartypants2 5 minutes ago
Multiple failure? That's according to you. Not according to normal interpretation of contract law, especially given the multiple breaches of contract and outright fraud by XTI as clearly delineated in XERI's complaint and subsequent court filings against them. And your absurd accusation that XERI ne
XERI
Budots Budots 6 minutes ago
$UNCY Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
https://finance.yahoo.com/news/unicycive-therapeutics-announces-u-fda-12000
UNCY
Budots Budots 6 minutes ago
$UNCY Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
https://finance.yahoo.com/news/unicycive-therapeutics-announces-u-fda-12000
UNCY
BEIJING BILL BEIJING BILL 6 minutes ago
It's still going up clownshows ... Cheechee cheee ..
POET
Gonzal Gonzal 6 minutes ago
Hans should just partner with Starbucks and ask them if they would like to have a division of cannabis/coffee shops and be the Starbucks of Weed
MEDH
pdmihopefull pdmihopefull 6 minutes ago
All you suckers buying these useless shares... lmao
KGKG
36Knuckle 36Knuckle 6 minutes ago
I...for what it's worth...(remember wooden nickels)...will buy 1's...
if it makes it easier to exit, so be it...
if Chad pulls his head out, so be it?
They won't come cheaper...
SFLM
konshe konshe 6 minutes ago
just need one news to see 0.003.
ASII
koolmc koolmc 6 minutes ago
amc nice going up on it's own don't need the other stock to go to move this now, this one has numbers to back it up now.
AMC
PROPHET-of-PROFITS PROPHET-of-PROFITS 7 minutes ago
$rdar what we are seeing is the last of the debt shares being sold off. once this is done rdar will head towards a penny.
bought 4m more this am myself. they're debt free...
RDAR
TJG TJG 7 minutes ago
I agree, they brought in this hot shot new board of directors duo and they have not done an damn thing.... and unfortunately there are a ton of OTC traders who have no clue what the wash sale rule is... they do not know that if you sell today you can not claim the loss if you buy back in before 30 d
AFFU

Your Recent History

Delayed Upgrade Clock